Description

VILDASMART M 50/1000 MG

Indications

VILDASMART M 50/1000 MG is primarily indicated for the management of type 2 diabetes mellitus in adults. It is particularly useful for patients who require improved glycemic control alongside a comprehensive diabetes management plan, including diet and exercise. This medication is often prescribed for individuals who are unable to achieve adequate glycemic control with diet and exercise alone or those who are already on other antidiabetic medications.

Mechanism of Action

VILDASMART M combines two active ingredients: Vildagliptin and Metformin. Vildagliptin is a DPP-4 inhibitor that works by increasing the levels of incretin hormones, which in turn increase insulin secretion from the pancreas in response to meals. It also decreases glucagon secretion, which reduces hepatic glucose production. Metformin, on the other hand, primarily acts by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues. Together, these mechanisms help to lower blood glucose levels effectively.

Pharmacological Properties

VILDASMART M exhibits a dual mechanism of action that targets both insulin secretion and insulin sensitivity. Vildagliptin has a rapid onset of action, typically within one to two hours after administration, with a peak effect occurring around one hour post-dose. Metformin has a slower onset of action, with its effects becoming noticeable over several days. The pharmacokinetics of VILDASMART M show that it is well-absorbed from the gastrointestinal tract, with a bioavailability of approximately 90% for Metformin and around 85% for Vildagliptin. The elimination half-life of Vildagliptin is approximately 2 hours, while Metformin has a half-life of about 6 hours, necessitating multiple daily doses for optimal glycemic control.

Contraindications

VILDASMART M should not be used in patients with a known hypersensitivity to either Vildagliptin or Metformin. It is contraindicated in individuals with severe renal impairment (eGFR < 30 mL/min), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in patients with severe liver dysfunction. Additionally, it is not recommended for use during pregnancy and lactation unless the potential benefits outweigh the risks.

Side Effects

Common side effects associated with VILDASMART M include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort. These symptoms are generally mild to moderate and often resolve with continued use. Other potential side effects may include hypoglycemia, especially when used in conjunction with other antidiabetic agents. Rare but serious side effects include lactic acidosis, pancreatitis, and allergic reactions. Patients should be monitored for any unusual symptoms and report them to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of VILDASMART M is typically 50 mg of Vildagliptin and 1000 mg of Metformin, administered once daily. Depending on the patient’s glycemic response and tolerability, the dose may be adjusted. The maximum recommended dose should not exceed 100 mg of Vildagliptin and 2000 mg of Metformin per day. It is advised to take the medication with meals to minimize gastrointestinal side effects and enhance absorption. Regular monitoring of renal function is essential, particularly in elderly patients or those with existing renal issues.

Interactions

VILDASMART M may interact with other medications, which could enhance or diminish its effects. Concomitant use of diuretics, corticosteroids, or other medications that affect blood glucose levels may require dose adjustments. Alcohol consumption should be limited, as it can increase the risk of lactic acidosis and hypoglycemia. Additionally, the use of certain medications that impair renal function may increase the risk of Metformin accumulation and subsequent lactic acidosis. A thorough medication review is recommended prior to initiating therapy with VILDASMART M.

Precautions

Patients using VILDASMART M should be monitored closely for signs of lactic acidosis, particularly those with risk factors such as renal impairment, dehydration, or concurrent use of medications that may affect renal function. It is essential to ensure adequate hydration and to avoid situations that may lead to dehydration. Patients should also be advised to maintain regular follow-up appointments to monitor their glycemic control and overall health status. Caution should be exercised in patients with a history of pancreatitis, as there may be an increased risk of developing this condition with DPP-4 inhibitors.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of VILDASMART M in managing type 2 diabetes. In randomized controlled trials, patients treated with VILDASMART M showed significant reductions in HbA1c levels compared to those receiving placebo or monotherapy with either Vildagliptin or Metformin. The combination therapy was associated with a favorable safety profile, with a low incidence of hypoglycemia and gastrointestinal side effects. Long-term studies have indicated that VILDASMART M not only helps in achieving glycemic control but also contributes to weight neutrality, making it a suitable option for overweight patients.

Conclusion

VILDASMART M 50/1000 MG is an effective and well-tolerated option for the management of type 2 diabetes mellitus. Its dual mechanism of action helps in achieving optimal glycemic control while minimizing the risk of hypoglycemia. However, careful patient selection, monitoring for side effects, and consideration of potential drug interactions are crucial for ensuring safe and effective therapy. As with any medication, it is important for patients to engage in a comprehensive diabetes management plan that includes lifestyle modifications alongside pharmacotherapy.